Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 23, 2026

Eos Energy Announces Expiration and Results of Rights Offering

View original at globenewswire.com
Eos Energy Announces Expiration and Results of Rights Offering PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As of the Expiration Date, the Company received subscriptions for 6,885,218 Units offered in the rights offering, based on tabulation by Broadridge.

    60% confidence
  • The Subscription Agent is expected to distribute the shares, warrants, and sale proceeds on or about August 3, 2026.

    60% confidence
  • Approximately $263 million in gross proceeds have been raised in support of Frontier Power USA, exceeding the Company's original target, and is expected to initially support more than $1 billion of deployable project capital.

    60% confidence
  • The Company has applied to list its Warrants on the Nasdaq Capital Market under the symbol EOSEW, but no assurance can be given the application will be approved.

    60% confidence
  • The Company expects to receive aggregate gross proceeds from the rights offering of $37.7 million.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com